Prostate cancer

GU011

A PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL OF PROSTATE OLIGOMETASTATIC RADIOTHERAPY WITH OR WITHOUT ANDROGEN DEPRIVATION THERAPY IN OLIGOMETASTATIC PROSTATE CANCER (NRG PROMETHEAN)

Trial overview

Topic

NRG-GU011

Disease

Prostate cancer

Description

Compare conventional radiological progression-free survival (rPFS) for positron emission tomography (PET)-detected, biochemically recurrent, oligometastatic, castration-sensitive prostate cancer patients treated with SABR plus placebo vs. SABR plus relugolix.

Contact

Michigan

Maria Pappas

Florida

Peggy Mouradian

South Carolina

Marissa Elderbaum

Physicians

John Vito Antonucci

MD

Radiation Oncologist

Madison Heights (Radiation oncology) +3

Alvaro A. Martinez

MD, FACR, FABS, FASTRO

Radiation Oncologist

Pontiac (Radiation oncology) +4

Michael I. Ghilezan

MD, PhD

Radiation Oncologist

Pontiac (Radiation oncology) +3

Frank A. Vicini

MD, FACR, FASTRO, FABS

Radiation Oncologist

Farmington Hills (Radiation oncology) +2

Eduardo B. Fernandez

MD, PhD, FACRO, FASTRO

Radiation Oncologist

Aventura (Radiation oncology) +3

Christopher T. Chen

MD, FACRO

Radiation Oncologist

Pembroke Pines (Radiation oncology) +1

Patrick M. Francke

MD, FACRO

Radiation Oncologist

Myrtle Beach (Radiation oncology)